LGVN - Longeveron selects clinical research organization for phase 2 Alzheimer's disease trial

Longeveron (NASDAQ:LGVN) announces the selection of Biorasi as its clinical research organization (CRO) to help conduct its Phase 2 trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects. Biorasi has extensive experience in the management and execution of neurology clinical studies, with deep experience in phase I through IV trials, both in the U.S. and globally. Longeveron expects to initiate the trial by year-end, or in the first quarter of 2022. Shares up more than 3% premarket.

For further details see:

Longeveron selects clinical research organization for phase 2 Alzheimer’s disease trial